Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity
Alzheimer’s disease (AD) is the most common form of neurodegeneration and dementia. The endocannabinoid (ECB) system has been proposed as a novel therapeutic target to treat AD. The present study explores the expression of the ECB system, the ECB-related receptor GPR55, and cognitive functions (nove...
Main Authors: | Dina Medina-Vera, Cristina Rosell-Valle, Antonio J. López-Gambero, Juan A. Navarro, Emma N. Zambrana-Infantes, Patricia Rivera, Luis J. Santín, Juan Suarez, Fernando Rodríguez de Fonseca |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/9/11/377 |
Similar Items
-
The Expression of the Endocannabinoid Receptors CB2 and GPR55 Is Highly Increased during the Progression of Alzheimer’s Disease in <i>App<sup>NL-G-F</sup></i> Knock-In Mice
by: Dina Medina-Vera, et al.
Published: (2023-05-01) -
Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55
by: Raquel Guerrero-Alba, et al.
Published: (2019-01-01) -
APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology
by: Kristine M. Tran, et al.
Published: (2025-01-01) -
Mode of administration influences plasma levels of active Centella asiatica compounds in 5xFAD mice while markers of neuroinflammation remain unaltered
by: Alex B. Speers, et al.
Published: (2024-03-01) -
A systematic review and meta-analysis of tau phosphorylation in mouse models of familial Alzheimer's disease
by: Malamati Kourti, et al.
Published: (2024-03-01)